S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 033 JPY 1.08% Market Closed
Market Cap: 92.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sosei Group Corp
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Deferred Income Tax
ÂĄ2.3B
CAGR 3-Years
18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Deferred Income Tax
ÂĄ46.6B
CAGR 3-Years
-57%
CAGR 5-Years
-44%
CAGR 10-Years
-16%
Daiichi Sankyo Co Ltd
TSE:4568
Deferred Income Tax
ÂĄ11.3B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
-13%
Otsuka Holdings Co Ltd
TSE:4578
Deferred Income Tax
ÂĄ26.3B
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Deferred Income Tax
ÂĄ3.4B
CAGR 3-Years
-25%
CAGR 5-Years
-18%
CAGR 10-Years
-11%
Astellas Pharma Inc
TSE:4503
Deferred Income Tax
ÂĄ23.6B
CAGR 3-Years
36%
CAGR 5-Years
37%
CAGR 10-Years
67%
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
92.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 22%
Intrinsic Value
Price
S

See Also

What is Sosei Group Corp's Deferred Income Tax?
Deferred Income Tax
2.3B JPY

Based on the financial report for Sep 30, 2024, Sosei Group Corp's Deferred Income Tax amounts to 2.3B JPY.

What is Sosei Group Corp's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 5Y
3%

Over the last year, the Deferred Income Tax growth was 14%. The average annual Deferred Income Tax growth rates for Sosei Group Corp have been 18% over the past three years , 3% over the past five years .

Back to Top